丁酸梭菌MIYAIRI （CBM588）联合派姆单抗治疗晚期尿路上皮癌的预后影响：一项回顾性队列研究

IF 1.9 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-08-05 DOI:10.1002/cnr2.70308

Junya Arima, Hirofumi Yoshino, Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida

{"title":"丁酸梭菌MIYAIRI （CBM588）联合派姆单抗治疗晚期尿路上皮癌的预后影响：一项回顾性队列研究","authors":"Junya Arima, Hirofumi Yoshino, Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida","doi":"10.1002/cnr2.70308","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; <i>p</i> = 0.004) and overall survival (OS; <i>p</i> = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, <i>p</i> = 0.0008) and OS (hazard ratio: 0.105, <i>p</i> = 0.0056).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70308","citationCount":"0","resultStr":"{\"title\":\"Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study\",\"authors\":\"Junya Arima, Hirofumi Yoshino, Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida\",\"doi\":\"10.1002/cnr2.70308\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and Results</h3>\\n \\n <p>The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; <i>p</i> = 0.004) and overall survival (OS; <i>p</i> = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, <i>p</i> = 0.0008) and OS (hazard ratio: 0.105, <i>p</i> = 0.0056).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 8\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70308\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70308\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景益生菌产品CBM588与免疫检查点抑制剂（ICIs）联合使用可改善几种癌症的预后。单独使用派姆单抗作为尿路上皮癌（UC）的二线治疗，预后仅延长3个月。这是一项回顾性研究，旨在研究CBM588联合派姆单抗治疗晚期UC的疗效。方法与结果本研究纳入44例一线顺铂或卡铂化疗后出现复发或进展的患者。该研究比较了33例单独使用派姆单抗治疗的患者和11例使用CBM588加派姆单抗治疗的患者，中位观察期为12个月。CBM588联合派姆单抗显著改善无进展生存期(PFS；p = 0.004)和总生存期(OS；P = 0.02)。多因素分析发现CBM588是PFS（风险比：0.074,p = 0.0008）和OS（风险比：0.105,p = 0.0056）的重要预后因素。结论CBM588联合ICI治疗UC疗效确切。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study

查看原文本刊更多论文

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study

Background

Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.

Aims

This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.

Methods and Results

The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).